Lv1
50 积分 2021-10-25 加入
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology
12天前
已完结
Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population
14天前
已完结
Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments
1个月前
已完结
Biomarkers for immunotherapy of hepatocellular carcinoma
1个月前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
1个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
1个月前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
1个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
1个月前
已完结
Current and emerging strategies for the prevention of hepatocellular carcinoma
1个月前
已完结
Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma
1个月前
已完结
皖公网安备34019202002308
